Document Detail


Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts.
MedLine Citation:
PMID:  22056855     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Bevacizumab is a monoclonal antibody against vascular endothelial growth factor. Severe pulmonary haemorrhage (PH) is a rare but serious potential adverse event associated with bevacizumab therapy for advanced non-squamous non-small-cell lung cancer (NSCLC).
METHODS: A panel of expert oncologists, pulmonologists and radiologists reviewed the available data to identify predictive factors for PH in order to help guide physicians using bevacizumab in patients with NSCLC.
RESULTS: Patients with NSCLC are at an increased risk of PH owing to the underlying disease process. Patients with squamous histology and/or a history of grade ≥ 2 haemoptysis (≥ 2.5 ml per event) should not receive bevacizumab. No clinical or radiological features (including cavitation and central tumour location) reliably predict severe PH in bevacizumab-treated patients. Major blood vessel infiltration and bronchial vessel infiltration, encasement and abutting may predict PH; however, standardised radiological criteria for defining infiltration have not been established. Eligibility for bevacizumab is not affected by patient age, performance status or anticoagulation or antiplatelet therapy.
CONCLUSIONS: An individualised risk-benefit assessment should be undertaken in all patients with NSCLC in whom bevacizumab is being considered. Further research is required to elucidate the mechanisms underlying PH and the clinical risk factors.
Authors:
M Reck; F Barlesi; L Crinò; C I Henschke; D Isla; S Stiebeler; D R Spigel
Related Documents :
759635 - Early observations on 31 adults with non-refluxing colon conduits.
21681995 - Psychometric development and reliability analysis of a patient satisfaction with interp...
10023345 - Fatal serratia marcescens meningitis and myocarditis in a patient with an indwelling ur...
21995475 - Bedside review of patient care in an emergency department: the cow round.
7272695 - Admission policy for patients following head injury.
20534035 - Liposomal amphotericin b in the treatment of visceral leishmaniasis in immunocompromise...
Publication Detail:
Type:  Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2011-11-04
Journal Detail:
Title:  Annals of oncology : official journal of the European Society for Medical Oncology / ESMO     Volume:  23     ISSN:  1569-8041     ISO Abbreviation:  Ann. Oncol.     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-04-25     Completed Date:  2012-09-07     Revised Date:  2013-06-27    
Medline Journal Info:
Nlm Unique ID:  9007735     Medline TA:  Ann Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1111-20     Citation Subset:  IM    
Affiliation:
Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany. dr.martin.reck@web.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiogenesis Inhibitors / adverse effects,  therapeutic use
Antibodies, Monoclonal, Humanized / adverse effects*,  therapeutic use
Carcinoma, Non-Small-Cell Lung / complications,  diagnosis,  drug therapy*
Consensus
Expert Testimony
Forecasting / methods
Hemorrhage / chemically induced,  diagnosis*,  etiology,  therapy*
Humans
Lung Diseases / chemically induced,  diagnosis*,  etiology,  therapy*
Lung Neoplasms / complications,  diagnosis,  drug therapy*
Prognosis
Risk Factors
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V/bevacizumab
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized...
Next Document:  Dosimetric evaluation of breast radiotherapy in a dynamic phantom.